Race Oncology Ltd (ASX: RAC) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Race Oncology Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $454.42 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 159.44 million
Earnings per share -0.048
Dividend per share N/A
Year To Date Return -20.56%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Race Oncology Ltd (ASX: RAC)
Latest News

Lab technician analyses a sample in a laboratory for a clinical trial
Healthcare Shares

Race Oncology (ASX:RAC) share price rises following preclinical discovery

Key points The Race Oncology share price is up as high as 2.8% today A new discovery relating to heart …

Read more »

A health professional wearing green scrubs and a face mask and stethoscope uses his mobile phone.
Healthcare Shares

In the green: Here are the 5 best ASX healthcare shares of 2021

Returns in the ASX healthcare basket were fairly robust throughout 2021. Sector earnings saw a return to pre-COVID levels as …

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Here’s why the Race Oncology (ASX:RAC) share price is edging higher

The Race Oncology Ltd (ASX: RAC) share price is climbing today on the back of the company’s latest capital raise. During morning …

Read more »

A medical specialist holds a red heart connected via technology and artificial intelligence (AI)
Healthcare Shares

Here’s why the Race Oncology (ASX:RAC) share price is climbing today

The Race Oncology Ltd (ASX: RAC) share price is rising today after the company announced positive findings on its anti-cancer drug trials. …

Read more »

A man in a white coat holds a laptop in one hand and his head in the other, it's bad news.
Healthcare Shares

Why is the Race Oncology (ASX:RAC) share price plunging 12% today?

Investors are selling off shares in precision oncology company Race Oncology Ltd (ASX: RAC) after a flurry of market sensitive …

Read more »

ASX shares downgrade A young woman with tattoos puts both thumbs down and scrunches her face with the bad news.
Share Fallers

Why Bapcor, Mayne Pharma, Race Oncology, and TechnologyOne shares are sinking

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) has just dropped into the red. At the time of writing, the …

Read more »

man jumping along increasing bar graph signifying jump in alumina share price
Healthcare Shares

Racing higher: Race Oncology (ASX:RAC) share price jumps 13% on study breakthrough

Shares in Australian pharmaceutical company Race Oncology Ltd (ASX: RAC) jumped higher today and finished 13% in the green. Investors …

Read more »

two laboratory researchers in white coats and gloves sit side by side with scientific equipment and a computer screen conducting medical related research.
Share Gainers

Why the Race Oncology (ASX:RAC) share price is up on Monday

Shares in Australian pharmaceutical company Race Oncology Ltd (ASX: RAC) are up 4% from the open to now trade at …

Read more »

RAC ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Race Oncology Ltd

Race Oncology Ltd is an Australian pharmaceutical company whose business model is to pursue and bring to market later stage assets, principally in the cancer field.

RAC Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
27 Jan 2022 $2.85 $-0.01 -0.35% 376,428 $2.92 $2.98 $2.76
25 Jan 2022 $2.86 $-0.14 -4.67% 622,236 $2.99 $3.07 $2.86
24 Jan 2022 $3.00 $-0.10 -3.23% 547,148 $3.09 $3.09 $2.96
21 Jan 2022 $3.10 $-0.11 -3.43% 280,454 $3.16 $3.16 $3.09
20 Jan 2022 $3.21 $0.03 0.94% 139,969 $3.19 $3.21 $3.14
19 Jan 2022 $3.18 $-0.04 -1.24% 388,445 $3.20 $3.20 $3.15
18 Jan 2022 $3.22 $0.00 0.00% 68,335 $3.28 $3.29 $3.21
17 Jan 2022 $3.22 $0.01 0.31% 93,541 $3.23 $3.27 $3.21
14 Jan 2022 $3.21 $-0.03 -0.93% 138,334 $3.24 $3.27 $3.20
13 Jan 2022 $3.24 $-0.06 -1.82% 244,545 $3.32 $3.32 $3.22
12 Jan 2022 $3.30 $-0.02 -0.60% 128,844 $3.34 $3.35 $3.28
11 Jan 2022 $3.32 $0.01 0.30% 125,378 $3.31 $3.36 $3.28
10 Jan 2022 $3.31 $-0.10 -2.93% 460,864 $3.41 $3.41 $3.26
07 Jan 2022 $3.41 $0.09 2.71% 167,784 $3.32 $3.43 $3.32
06 Jan 2022 $3.32 $-0.16 -4.60% 351,821 $3.43 $3.45 $3.30
05 Jan 2022 $3.48 $-0.17 -4.66% 361,212 $3.66 $3.66 $3.48
04 Jan 2022 $3.65 $0.05 1.39% 222,192 $3.62 $3.72 $3.62
31 Dec 2021 $3.60 $-0.05 -1.37% 100,947 $3.67 $3.67 $3.56
30 Dec 2021 $3.65 $-0.06 -1.62% 208,616 $3.73 $3.78 $3.56

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
10 Jan 2022 John Cullity Sell 300 $995,174
On-market trade.
21 Dec 2021 Daniel Tillett Issued 10 $30,000
Participation in share purchase plan.
21 Dec 2021 Phillip(Phil) Lynch Issued 10 $30,000
Participation in share purchase plan.
21 Dec 2021 Mary Harney Issued 10 $30,000
Participation in share purchase plan.
14 Dec 2021 Daniel Tillett Buy 2 $7,732
On-market trade.
10 Dec 2021 Daniel Tillett Buy 17 $59,188
On-market trade.
12 Nov 2021 John Cullity Buy 3 $710,000
Exercise of options.
12 Nov 2021 John Cullity Exercise 3 $710,000
Exercise of options.
04 Nov 2021 John Cullity Sell 217 $709,999
On-market trade.
02 Sep 2021 John Cullity Sell 61 $192,798
On-market trade.
23 Aug 2021 John Cullity Exercise 1 $187,499
Exercise of options.
23 Aug 2021 John Cullity Buy 1 $187,499
Exercise of options.
28 Jun 2021 Mary Harney Buy 5 $20,118
On-market trade.
19 May 2021 Daniel Tillett Issued 672 $2,152,000
Issue of options.
19 May 2021 Phillip(Phil) Lynch Issued 20 $67,065
Issue of options.
19 May 2021 Mary Harney Issued 400 $1,280
Issue of options.
15 Mar 2021 Mary Harney Buy 8 $31,567
On-market trade.
10 Mar 2021 Daniel Tillett Buy 4 $420,750
Exercise of options.
10 Mar 2021 Daniel Tillett Exercise 4 $420,750
Exercise of options.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Dr John Cullity Executive ChairmanExecutive Director Apr 2018
Dr Cullity is Managing Director at BioSynergy Partners, a New York and Melbourne based advisory recently spun out of Torreya - the renowned life sciences investment bank. He additionally serves on the Boards of several life sciences companies including Ceramedix (seeded by Torreya). At Torreya, he provided strategic advisory on Mergers and Acquisitions, Partnering and Financing to life-science companies worldwide. Prior to joining Torreya, he was a senior member of the Business Development team at Sanofi Pharmaceuticals, where he led buy side transactions in oncology and diabetes. Earlier in his career, Dr Cullity was Head of Strategic Pricing and Reimbursement at Sanofi, Director of Health Economics at Schering-Plough, and Consultant at A.T. Kearney. He has also worked at the World Bank and the World Health Organisation.
Dr Daniel Tillett Chief Scientific OfficerExecutive Director Sep 2019
Dr Tillett is the CEO and founder of Nucleics Pty Ltd, a private biotechnology company in the genomics space. He was previously a Senior Lecturer within the School of Pharmacy at La Trobe University where he lectured on biochemistry, biotechnology, pharmacy, microbiology and virology. Dr Tillett's Ph.D on the molecular genetics and biochemistry of microcystin toxin production was awarded by the University of New South Wales in 2000.
Mr Phillip(Phil) R Lynch Chief Executive OfficerManaging Director Jun 2020
Mr Lynch has a career spanning more than 30 years in the Asia Pacific region with Johnson & Johnson. He is an executive and board director, with a diverse background across corporate development, strategy, financial performance, marketing and governance. In his former role as Vice President of Commercial Growth and Innovation at Johnson & Johnson Asia Pacific (J&J AP), 2016 - 2019), Mr Lynch partnered with the Mergers and Acquisitions team to drive the integration and growth of acquired businesses. He retired from J&J AP in December 2019 following the >$2b acquisition and integration of a significant Japanese business. Mr Lynch was previously the Managing Director and CEO of J&J Pacific (AU/NZ - 2009 to 2015). He had further leadership roles across the Asia Pacific region, including Managing Director of various J&J divisions in Thailand, Vietnam, and Singapore. He is currently the Chair of Consumer Health Products Australia.
Ms Mary Harney Non-Executive Director Feb 2021
Ms Harney is the Director of specialist consulting firm Mary Harney Advisory providing leadership, governance and strategic advice across innovation industries such as health, biotech and agriculture. She currently also serves as Chairman of private Australian biotech Oncology One Pty Ltd, a cancer drug discovery company. Ms Harney was formerly the CEO of Royal Australasian College of Surgeons; CEO of Gardiner Research Foundation; COO and Director of Office of Cancer Research for Peter MacCallum Hospital, and; COO of Cerylid Biosciences. Other former roles were with CSL, Amrad, BIOPROPERTIES and Royal Melbourne Hospital.
Mr Peter Webse Company Secretary Aug 2016
-
Peter Webse Company Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Dr Daniel Tillett 13,450,000 9.31%
Dr William James Garner 8,979,939 6.22%
Mr Phillip Richard Perry 5,715,694 3.96%
Biosynergy Partners Pty Ltd 3,787,878 2.62%
BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp> 2,452,236 1.70%
Mr Mark Phillip Juan 2,301,316 1.59%
Mr Anthony James Robinson <The Peeko Family No 86 A/C> 1,600,000 1.11%
Mr Phillip Richard Perry & Mrs Tetyana Perry <Doneska Super Fund A/C> 1,490,000 1.03%
Mr Kenneth Barry Ridley & Mrs Catherine Mary Ridley <Ridley Retirement Fund A/C> 1,200,000 0.83%
Citicorp Nominees Pty Limited 1,140,603 0.79%
Mr Kimberley Ross Gartrell & Mrs Jennifer Margaret Gartrell <K&J Gartrell Super Fund A/C> 1,125,000 0.78%
Mr Sandor Helby 1,018,000 0.71%
Mr Andrew Jacobs 970,223 0.67%
Mr Brian James Walker 707,290 0.49%
Mr Graeme Stewart Pocknall & Mrs Vivienne Glynis Pocknall 617,830 0.43%
T&G Corporation Pty Ltd 589,400 0.41%
Mr Simon Rogers <Rogers Family A/C> 577,167 0.40%
Ditthavong & Steiner PC 538,478 0.37%
Beppe Super Pty Limited <Pake Superannuation Fund A/C> 532,000 0.37%
The Trust Company (Australia) Limited <MOF A/C> 6 4.30%

Profile

since

Note